SCHEMBL4498009

SCHEMBL4498009

CC(C)(O)c1ccc(-c2ccc(C3(C(N)=O)CC3)cc2F)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 10/20 0.60
CYP2C19 P33261 6/20 0.53
CYP3A4 P08684 6/20 0.53
CYP2C9 P11712 6/20 0.53
CYP2D6 P10635 3/20 0.53
AKR1C3 P42330 6/20 0.51
AKR1C2 P52895 6/20 0.51
AKR1C1 Q04828 3/20 0.51
AKR1B10 O60218 1/20 0.51
AKR1C4 P17516 1/20 0.51
CTSK P43235 2/20 0.49
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509220 0.89 APP (0.77) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4506397 0.82 CTSK (0.40) APPCYP2C9CTSK
SCHEMBL5011741 0.81 APP (0.55) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4513813 0.78 APP (0.55) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL5009745 0.78 APP (0.55) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4505580 0.78 APP (0.55) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4502966 0.78 SYK (0.46) APPCYP2C9AKR1C3AKR1C2CTSK
SCHEMBL4514275 0.77 APP (0.52) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4513629 0.77 APP (0.52) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4504114 0.76 APP (0.46) APPCYP2C19CYP3A4CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US claimed
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MAOB, MAOA, XDH APP 1024/4885CYP2C19 66/4885CYP3A4 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.